Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marla C Dubinsky

Showing results (181-190 of 286) with videos related to

Pageof 29
Sort By:
Inflammatory Bowel Diseases|March 4, 2025
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical ProgramBruce E Sands, Marla C Dubinsky, Paulo G Kotze, et al.
Crohn'S & Colitis 360|February 13, 2023
Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug MonitoringAmy Hemperly, Marla C Dubinsky, Andres Yarur, et al.
Gastroenterology|August 2, 2003
6-thioguanine can cause serious liver injury in inflammatory bowel disease patientsMarla C Dubinsky, Eric A Vasiliauskas, Hardeep Singh, et al.
Inflammatory Bowel Diseases|June 10, 2023
Health Care Disparities, Social Determinants of Health, and Emotional Impacts in Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient SurveyFlorence-Damilola Odufalu, Marla C Dubinsky, Laurent Peyrin-Biroulet, et al.
BMJ Open Gastroenterology|September 1, 2025
Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programmeMaría Chaparro, Remo Panaccione, Bruce E Sands, et al.
Journal of Pharmacy Practice|April 8, 2021
Improved Smoking Cessation Rates in a Pharmacist-Led Program Embedded in an Inflammatory Bowel Disease Specialty Medical HomeStacy Saithy Tse, Bruce E Sands, Laurie Keefer, et al.
Therapeutic Advances in Gastroenterology|March 3, 2025
Potential predictors of efficacy outcomes following tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a post hoc analysis of outcomes from the RIVETING studyJoana Torres, Geert R D'Haens, Miguel Regueiro, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 24, 2025
Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD StudyBruce E Sands, Stefan Schreiber, Marla C Dubinsky, et al.
Inflammatory Bowel Diseases|October 7, 2019
Inflammatory Pouch Conditions Are Common After Ileal Pouch Anal Anastomosis in Ulcerative Colitis PatientsMaia Kayal, Michael Plietz, Anam Rizvi, et al.
Inflammatory Bowel Diseases|April 5, 2022
Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical ProgramMarla C Dubinsky, Fernando Magro, Flavio Steinwurz, et al.
Pageof 29

Showing results (181-190 of 286) with videos related to

Sort By:
Pageof 29
Inflammatory Bowel Diseases|March 4, 2025
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical ProgramBruce E Sands, Marla C Dubinsky, Paulo G Kotze, et al.
Crohn'S & Colitis 360|February 13, 2023
Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug MonitoringAmy Hemperly, Marla C Dubinsky, Andres Yarur, et al.
Gastroenterology|August 2, 2003
6-thioguanine can cause serious liver injury in inflammatory bowel disease patientsMarla C Dubinsky, Eric A Vasiliauskas, Hardeep Singh, et al.
Inflammatory Bowel Diseases|June 10, 2023
Health Care Disparities, Social Determinants of Health, and Emotional Impacts in Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient SurveyFlorence-Damilola Odufalu, Marla C Dubinsky, Laurent Peyrin-Biroulet, et al.
BMJ Open Gastroenterology|September 1, 2025
Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programmeMaría Chaparro, Remo Panaccione, Bruce E Sands, et al.
Journal of Pharmacy Practice|April 8, 2021
Improved Smoking Cessation Rates in a Pharmacist-Led Program Embedded in an Inflammatory Bowel Disease Specialty Medical HomeStacy Saithy Tse, Bruce E Sands, Laurie Keefer, et al.
Therapeutic Advances in Gastroenterology|March 3, 2025
Potential predictors of efficacy outcomes following tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a post hoc analysis of outcomes from the RIVETING studyJoana Torres, Geert R D'Haens, Miguel Regueiro, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 24, 2025
Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD StudyBruce E Sands, Stefan Schreiber, Marla C Dubinsky, et al.
Inflammatory Bowel Diseases|October 7, 2019
Inflammatory Pouch Conditions Are Common After Ileal Pouch Anal Anastomosis in Ulcerative Colitis PatientsMaia Kayal, Michael Plietz, Anam Rizvi, et al.
Inflammatory Bowel Diseases|April 5, 2022
Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical ProgramMarla C Dubinsky, Fernando Magro, Flavio Steinwurz, et al.
Pageof 29